Publisher
Springer Science and Business Media LLC
Reference18 articles.
1. Pirker R, Szczesna A, von Pawel J et al (2008) FLEX: a randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbin (CV) versus CV alone in the first-line treatment of patients with advanced non-small lung cancer (NSCLC). Proc Am Soc Clin Oncol 26(Suppl):S1006; Abstr. #3
2. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab fon non-small cell lung cancer. N Engl J Med 355:2542–2550
3. Manegold C et al (2008) A phase III randomised study of first-line bevacizumab combined with cisplatin/gemcitabine in aptients with advanced or recurrent non-squameous non-small cell lung cancer. ESMO; Abstr. #LAB1
4. Shepherd FA, Rodriguez-Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353:123–132
5. Mok T, Wu l, Thongprasert S et al (2008) Phase III, randomized, open-label, first-line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) (IPASS). Ann Oncol 19(Suppl.8) LBA2